Abstract
Immediately after the annual scientific meeting of the American Society of Hematology (ASH), a select group of clinical and laboratory investigators in myeloproliferative neoplasms (MPN) is summoned to a post-ASH conference on chronic myeloid leukemia and the BCR-ABL1-negative MPN. The 6th such meeting occurred on December 13–14,2011, in La Jolla, California, USA, under the direction of its founder,Dr. Tariq Mughal. The current document is the first of two reports on this post-ASH event and summarizes the most recent preclinical and clinical advances in polycythemia vera, essential thrombocythemia,and primary myelofibrosis.
Publication types
-
Congress
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Clinical Trials as Topic
-
DNA Methylation
-
DNA, Neoplasm / chemistry
-
DNA, Neoplasm / genetics
-
Disease Progression
-
Drugs, Investigational / therapeutic use
-
Genes, Neoplasm*
-
Hematopoietic Stem Cell Transplantation
-
Hematopoietic Stem Cells / pathology
-
Histone Deacetylase Inhibitors / therapeutic use
-
Humans
-
Inflammation
-
Interferon alpha-2
-
Interferon-alpha / therapeutic use
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
-
Multicenter Studies as Topic
-
Myeloproliferative Disorders / drug therapy
-
Myeloproliferative Disorders / genetics*
-
Neoplasm Proteins / antagonists & inhibitors
-
Neoplasm Proteins / genetics
-
Polyethylene Glycols / therapeutic use
-
Prognosis
-
Recombinant Proteins / therapeutic use
-
Thalidomide / analogs & derivatives
-
Thalidomide / therapeutic use
-
Treatment Outcome
Substances
-
DNA, Neoplasm
-
Drugs, Investigational
-
Histone Deacetylase Inhibitors
-
Interferon alpha-2
-
Interferon-alpha
-
Neoplasm Proteins
-
Recombinant Proteins
-
Polyethylene Glycols
-
Thalidomide
-
pomalidomide
-
peginterferon alfa-2b
-
peginterferon alfa-2a